AGEN


Maxim Reiterates Buy On Agenus As Paradigm Shift Is Taking Hold In Immune-Based Therapeutics

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Agenus (NASDAQ:AGEN) with a $9 price target, which represents …

H.C. Wainwright Reiterates Buy On Agenus Following 2Q14 Results

In a research report issued this morning, H.C.

H.C. Wainwright Reiterates Buy On Agenus Following Phase 2 Data From Prophage Vaccine

In a research note released Tuesday, H.C.

Agenus Represents An Undervalued Player In The Immuno-Oncology Space, Says H.C. Wainwright

In a research note issued this morning, H.C.

Maxim Keeps ‘Buy’ On Agenus Following Phase 2 Trial Data From HerpV

In a research note issued today, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Agenus Inc. (AGEN) and a price target of $11, after AGEN announced the final data set …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts